Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 10/20 | 0.55 |
| ▸ | DRD3 | P35462 | 10/20 | 0.55 |
| ▸ | DRD1 | P21728 | 9/20 | 0.55 |
| ▸ | DRD5 | P21918 | 9/20 | 0.55 |
| ▸ | DRD4 | P21917 | 5/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6883015 | 0.94 | MAOA (0.59) | HTR2AHTR2CHTR2BDRD2DRD3 | |
| SCHEMBL29991420 | 0.92 | MAOA (0.55) | HTR2AHTR2CHTR2BDRD2DRD3 | |
| SCHEMBL2625798 | 0.92 | MAOA (0.55) | HTR2AHTR2CHTR2BDRD2DRD3 | |
| Nitric Acid SCHEMBL165780 | 0.86 | HTR2A (0.50) | HTR2AHTR2CHTR2BDRD2DRD3 | |
| SCHEMBL15962624 | 0.81 | — | — | |
| SCHEMBL2365814 | 0.81 | HTR2A (0.53) | HTR2AHTR2CHTR2BDRD2DRD3 | |
| SCHEMBL1905997 | 0.80 | DRD2 (0.58) | HTR2AHTR2CHTR2BDRD2DRD1 | |
| SCHEMBL2365665 | 0.80 | DRD2 (0.47) | HTR2AHTR2CDRD2DRD3DRD1 | |
| SCHEMBL15649743 | 0.79 | MET (0.42) | HTR2AHTR2CDRD2DRD3DRD1 | |
| Ammonia Solution, Strong SCHEMBL10465265 | 0.79 | HTR2A (0.67) | HTR2AHTR2CHTR2BPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328835-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3288946-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2017023679-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2016176177-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| EP-2939677-A1 | ADMINISTRATION OF LORCASERIN TO INDVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611781-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611427-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| CN-102648170-A | Processes for the preparation of 5-HT2C receptor agonists | ARENA PHARM INC | 2012-08-22 | — | — | CN | disclosed |
| WO-2010148207-A3 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2010148207-A2 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| EP-2001852-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007120517-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1411881-A4 | 5HT sb 2C /sb RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1411881-A2 | 5HT sb 2C /sb RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003086306-A2 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-0080779-B1 | 3-BENZAZEPINES AS ALPHA-2 ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1986-07-16 | — | — | EP | disclosed |
| US-4496558-A | Pharmaceutical compositions and methods for producing alpha antagonism | SMITHKLINE BECKMAN CORPORATION (US) | 1985-01-29 | — | — | US | disclosed |
| EP-0108170-A1 | 3-Benzazepines as alpha-2 antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1984-05-16 | — | — | EP | disclosed |
| EP-0080779-A1 | 3-Benzazepines as alpha-2 antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-08 | — | — | EP | disclosed |